Generate:Biomedicines aims to raise around $400 million in its IPO, which would mark the largest offering by a Massachusetts company since 2023. Generate:Biomedicines plans to raise around $400 million in its initial public offering — a sum that hasn’t been seen for several years amid more challenging economic times in the life sciences industry.

Original title: “Generate:Biomedicines targets $400M IPO amid biotech market thaw - Boston Business Journal”

The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.

Original title: “Merck Reorganizes Human Health Work Into Two New Units”

Ralph Abraham, a vocal vaccine skeptic who served at the agency for just three months, has stepped down due to “unforeseen family obligations,” according to the CDC.

Original title: “Kennedy Ally Departs CDC Amid Leadership Shake-Up”

Illustration: Allie Carl/Axios · Generate Biomedicines, a Flagship Pioneering-backed AI biotech, aims to raise as much as $425 million in an IPO Generate Biomedicines, a Flagship Pioneering-backed AI biotech, aims to raise as much as $425 million in an IPO. Why it matters: Generate is going public as the biotech IPO market reopens unevenly, with mixed debut performances. Proceeds will accelerate clinical trials.

Original title: “Generate Biomedicines files for $425M IPO to fund pipeline”

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. | Generate:Biomedicines is hoping to raise up to $425 million via an IPO, with the proceeds expected to bankroll its lead ... Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. | Generate:Biomedicines is hoping to raise up to $425 million via an IPO, with the proceeds expected to bankroll its lead antibody through respiratory disease trials. Generate:Biomedicines hopes to raise $425 million, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. There’s also GB-5267, an armored, MUC16-directed CAR-T developed in partnership with the Roswell Park Comprehensive Cancer Center and initially being aimed at platinum-resistant ovarian cancer. The biotech estimates $15 million of the proceeds will be needed to take GB-4362 and GB-5267 into the clinic. 'When the markets opened, we were ready': Why biotech IPOs are back for 2026 Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded biotech first disclosed its ambition to go public earlier this month but has only now attached figures to that strategy.

Original title: “Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials”

The Somerville-based company, which uses its proprietary AI system in drug engineering and development, is seeking to go public amid a jump in biotech and pharma IPO volume. The Somerville-based company, which uses its proprietary AI system in drug engineering and development, is seeking to go public amid a jump in biotech and pharma IPO volume.Generate Bio The company, which uses its proprietary AI system in drug engineering and development, is seeking to go public amid a jump in biotech and pharma IPO volume. First-time share sales for firms including Aktis Oncology Inc. and Veradermics Inc. since the start of the year have raised $1.4 billion, surpassing the $915 million raised in the same period in 2025, data compiled by Bloomberg show. Generate is developing medicine for people with severe asthma and chronic obstructive pulmonary disease (COPD), the filing shows. Board chair Noubar Afeyan, who co-founded Moderna Inc., controls 57 percent of Generate’s shares through Flagship Pioneering, an investment firm that creates and backs biotech companies. Generate was founded by Flagship Pioneering in 2018. Chief Executive Officer Michael Nally holds 6.4 percent of Generate’s shares, according to the filing. Generate’s IPO is being led by Goldman Sachs Group Inc.

Original title: “Flagship-backed Generate Biomedicines seeks $425 million in IPO - The Boston Globe”

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

Original title: “Merck to split cancer, specialty drug businesses in leadership shakeup”

A lower court had previously ruled for Sarepta in the companies’ long-running dispute, finding that REGENXBIO’s AAV patent was invalid because its elements were naturally occurring. The appeals court on Friday said that this original decision adopts a “narrow” view of the invention.

Original title: “REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta”

The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026.

Original title: “Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition”

Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off.

Original title: “Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test”

The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.

Original title: “Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy”

Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market that has seen listings pick up pace. Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market that has seen listings pick up pace. Backed by venture firm Flagship Pioneering, which has incubated several biotechs, including Moderna (MRNA.O), opens new tab, Generate is seeking to raise up to $425 million in its IPO by offering 25 million shares priced between $15 and $17 apiece. Sign up here. "The backing from Flagship Pioneering and partnerships with Novartis and Amgen, provides strong institutional credibility to the offering. Basil writes stories across the U.S. finance file including banks, asset managers, payment firms, insurers, and exchange operators. He also covers initial public offerings on U.S. exchanges and venture capital funding.

Original title: “Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO | Reuters”

Generate Biomedicines plans up to $425 million U.S. IPO Generate Biomedicines plans up to $425 million U.S. IPO ... Investing.com -- Generate Biomedicines has filed for an initial public offering on Monday, aiming to raise as much as $425 million in the United States. The biotechnology company plans to offer 25 million shares at a price range of $15 to $17 per share. The company focuses on immunology, oncology, and infectious diseases. The Cambridge, Massachusetts-based company was founded in 2018. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Generate Biomedicines plans up to $425 million U.S. IPO

Original title: “Generate Biomedicines plans up to $425 million U.S. IPO By Investing.com”

The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in its TDP-43-targeting PIONEER-ALS trial and EverythingALS' pharma consortia driving biomarker innovations and trial alignment.

Original title: “Historic ALS Investment Signals New Treatment Momentum”

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

Original title: “Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In”

After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and combination treatments, that seek to mirror the commercial success of Madrigal’s Rezdiffra.

Original title: “Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play”

Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday.The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range of $15 to $17. Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday.The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range of $15 to $17. - Renaissance Capital Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range of $15 to $17.

Original title: “GENB IPO News - Asthma-focused AI biotech Generate Biomedicines sets terms for $400 million IPO”

Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

Original title: “Grail’s multi-cancer early detection test misses study goal”

In a 6-3 decision, the court rejected President Trump's claim that a 1977 law gave him the authority to impose broad tariffs globally.

Original title: “Supreme Court invalidates Trump tariffs based on emergency powers”

The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.

Original title: “Trump sets fresh 10% global tariff — and plans to increase further”